Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American ...
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced ...